Sumitomo Mitsui Trust Group Inc. Has $117.24 Million Position in Beam Therapeutics Inc. $BEAM

Sumitomo Mitsui Trust Group Inc. boosted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) by 2.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,830,738 shares of the company’s stock after buying an additional 101,294 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Beam Therapeutics were worth $117,242,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BEAM. Allworth Financial LP increased its position in Beam Therapeutics by 7,080.0% in the 2nd quarter. Allworth Financial LP now owns 2,513 shares of the company’s stock valued at $43,000 after acquiring an additional 2,478 shares during the period. Daiwa Securities Group Inc. grew its stake in shares of Beam Therapeutics by 1,248.8% in the second quarter. Daiwa Securities Group Inc. now owns 3,817 shares of the company’s stock worth $65,000 after purchasing an additional 3,534 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Beam Therapeutics by 43.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,884 shares of the company’s stock valued at $66,000 after purchasing an additional 1,175 shares during the period. Bayforest Capital Ltd acquired a new stake in Beam Therapeutics in the third quarter valued at $114,000. Finally, Strs Ohio bought a new position in Beam Therapeutics during the 1st quarter worth $193,000. 99.68% of the stock is owned by institutional investors.

Beam Therapeutics Stock Performance

BEAM stock opened at $34.55 on Wednesday. The stock’s 50 day simple moving average is $25.84 and its 200 day simple moving average is $23.06. Beam Therapeutics Inc. has a fifty-two week low of $13.52 and a fifty-two week high of $36.44. The company has a market cap of $3.51 billion, a P/E ratio of -7.80 and a beta of 2.07.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.12). The firm had revenue of $9.70 million during the quarter, compared to analyst estimates of $12.83 million. Beam Therapeutics had a negative net margin of 744.41% and a negative return on equity of 42.86%. The company’s revenue was down 32.2% on a year-over-year basis. During the same period last year, the business posted ($1.17) EPS. Equities analysts predict that Beam Therapeutics Inc. will post -4.57 earnings per share for the current year.

Key Beam Therapeutics News

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Company/FDA alignment and extended cash runway materially de-risks BEAM-302 (in‑vivo AATD) and supports a valuation re-rate; management says runway now extends to 2029, reducing near‑term financing pressure. Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029
• Positive Sentiment: Beam outlined concrete 2026 pipeline goals (accelerated approval strategy for BEAM‑302 and potential BLA for risto‑cel), language that investors saw as moving the company from “platform” to execution and triggered a sharp share move. BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises
• Positive Sentiment: Company press release and media coverage confirm strategic prioritization of genetic‑disease and hematology franchises, explicit execution focus on late‑stage programs and an operating‑runway extension — all factors that support investor confidence in near‑term catalysts. Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating …
• Positive Sentiment: Coverage notes the stock hit a new 12‑month high as investors reacted to the above updates and the clearer regulatory/timing outlook for 2026 catalysts. Beam Therapeutics (NASDAQ:BEAM) Sets New 12-Month High – Here’s Why
• Neutral Sentiment: Analyst piece frames Beam’s shift as “platform → execution” and highlights reduced regulatory risk for BEAM‑302, but flags risto‑cel faces a crowded ex‑vivo SCD market; success depends on best‑in‑class data and timely BLA submission by end‑2026 — a mixed risk/reward read. Beam Therapeutics: Pivoting From Platform To Execution Stage
• Neutral Sentiment: Short‑interest report in the data feed shows an anomalous spike but returns 0 shares/NaN in the published fields — likely a reporting/data error; monitor for confirmed short interest changes that could pressure shares.

Wall Street Analysts Forecast Growth

BEAM has been the subject of a number of analyst reports. Benchmark restated a “speculative buy” rating on shares of Beam Therapeutics in a research report on Monday, November 17th. Evercore ISI began coverage on shares of Beam Therapeutics in a research report on Monday, November 24th. They set an “outperform” rating and a $35.00 target price for the company. Wall Street Zen downgraded shares of Beam Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. UBS Group started coverage on shares of Beam Therapeutics in a research report on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Beam Therapeutics in a research note on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.23.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.